Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers

No abstract is available for this paper.

• Publication year

  2024

• Venue

  Nature

• Publication date

  2024-11-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41586-024-08261-8PMID 39604730PMCID PMC12704925
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intra-tumoral T cells in pediatric brain tumors display clonal expansion and effector properties

  2024cited by this paper
• GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.

  2023cited by this paper
• Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction.

  2023cited by this paper
• The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity.

  2022cited by this paper
• GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas

  2022cited by this paper
• Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence.

  2022cited by this paper
• An NK-like CAR T cell transition in CAR T cell dysfunction.

  2021cited by this paper
• Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials

  2020cited by this paper
• scRepertoire: An R-based toolkit for single-cell immune receptor analysis.

  2020cited by this paper
• Layilin augments integrin activation to promote antitumor immunity

  2020cited by this paper
• scRepertoire: An R-based toolkit for single-cell immune receptor analysis

  2020cited by this paper
• Glypican-3–Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma

  2020influential reference
• Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

  2020cited by this paper
• Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer

  2020cited by this paper
• Fast, sensitive, and accurate integration of single cell data with Harmony

  2019cited by this paper
• TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion

  2019cited by this paper
• Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15

  2019cited by this paper
• c-Jun overexpression in CAR T cells induces exhaustion resistance

  2019cited by this paper
• Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

  2018cited by this paper
• Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia

  2018cited by this paper
• Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL.

  2018cited by this paper
• Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy

  2018cited by this paper
• CAR T‐cell therapy of solid tumors

  2017cited by this paper
• Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.

  2017cited by this paper
• Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients

  2016cited by this paper
• Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.

  2016cited by this paper
• Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity

  2016cited by this paper
• The Molecular Signatures Database Hallmark Gene Set Collection

  2015cited by this paper
• IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy.

  2015cited by this paper
• The Molecular Signatures Database (MSigDB) hallmark gene set collection.

  2015cited by this paper
• Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.

  2015cited by this paper
• Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.

  2015cited by this paper
• Glypican 3 overexpression in primary and metastatic Wilms tumors

  2014cited by this paper
• Functional Network Pipeline Reveals Genetic Determinants Associated with in Situ Lymphocyte Proliferation and Survival of Cancer Patients

  2014cited by this paper
• Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.

  2014cited by this paper
• Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

  2014cited by this paper
• First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma

  2013cited by this paper
• Immunohistochemical Expression of Glypican-3 in Pediatric Tumors: An Analysis of 414 Cases

  2013cited by this paper
• Glypican 3 expression in tumors with loss of SMARCB1/INI1 protein expression.

  2013cited by this paper
• Glypican-3: a new target for cancer immunotherapy.

  2011cited by this paper
• Inducible apoptosis as a safety switch for adoptive cell therapy.

  2011cited by this paper
• Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

  2010cited by this paper
• Immune regulation by 4‐1BB and 4‐1BBL: complexities and challenges

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.

  2008cited by this paper
• Janeway's immunobiology

  2007cited by this paper
• Glypican 3: A Novel Marker in Testicular Germ Cell Tumors

  2006cited by this paper
• An inducible caspase 9 safety switch for T-cell therapy.

  2005cited by this paper
• Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15

  2003cited by this paper
• Fatal Leukemia in Interleukin 15 Transgenic Mice Follows Early Expansions in Natural Killer and Memory Phenotype Cd8+ T Cells

  2001cited by this paper

• Asynchronous Transitions from High-Risk Hepatoblastoma to Carcinoma.

  2026cites this paper
• CAR-T cell therapy for pediatric solid tumors: armored CAR-T cells and beyond

  2026influential citation
• Navigating the frontier of CAR-T cell resistance: From underlying mechanisms to innovative therapeutic solutions.

  2026cites this paper
• Relapsed rhabdoid tumours and other non-nephroblastoma childhood and adolescent kidney tumours: perspectives from the HARMONICA collaboration.

  2026cites this paper
• Nano-/nanobio-technology-enhanced CAR-T cell therapy: engineering the next generation of immunotherapies

  2026cites this paper
• Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology.

  2026cites this paper
• CAR-T cell therapies are coming after glioblastoma: An overview of early phase clinical trials and future perspectives

  2026cites this paper
• Enhancement of B7-H3 chimeric antigen receptor-T cell efficacy via the coexistence effect of IL-7, IL-15 and CCL19 for pancreatic and lung xenograft tumors.

  2026cites this paper
• Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms

  2026cites this paper
• IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity.

  2026cites this paper
• Serum Outperforms Plasma for Glypican-3 Quantification in Hepatocellular Carcinoma—A Prospective Comparative Study

  2026cites this paper
• Targeting metabolic reprogramming to enhance adoptive immunotherapy: emerging mechanisms and translational perspectives.

  2026cites this paper
• From innate-like to innate: the next wave of off-the-shelf CAR immunotherapies

  2026cites this paper
• Frontiers of cytokine engineering in CAR cell therapy for cancer

  2026cites this paper
• Engineering the next generation of CAR T- cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance

  2026cites this paper
• Protocol to generate human stem cell-derived CD70-directed allogeneic CAR-NKT cells for treating renal cell carcinoma

  2026cites this paper
• CAR T cells: the missing piece needed to improve outcomes for children with cancer?

  2026cites this paper
• Converting ‘cold’ to ‘hot’ hepatocellular carcinoma for improved immunotherapy (Review)

  2026cites this paper
• Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy

  2026cites this paper
• Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab.

  2026cites this paper
• Glypican 3-targeted chimeric antigen receptor T cells secreting TROP2-directed bispecific T cell engagers exhibit potent efficacy against lung squamous cell carcinoma

  2026cites this paper
• CAR-T triggers TAM reeducation and adaptive anti-tumor response via TREM2 deficiency or CD40 agonist

  2026cites this paper
• Next generation CAR-T cells to tackle down solid tumors.

  2026cites this paper
• The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.

  2026cites this paper
• Characterizing renal complications in immune effector cell therapies in pediatric hematological and solid tumors

  2026cites this paper
• Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy

  2026cites this paper
• Synthetic Hybrid Receptors for Safer and Programmable T Cell Therapy

  2026cites this paper
• Inflammation and Cancer: Molecular Mechanisms and Therapeutic Targets

  2026cites this paper
• Strategies and mechanisms for the enhancement of chimeric antigen receptor T-cell functions.

  2026cites this paper
• Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

  2026cites this paper
• How can we balance risk and benefit of interleukin-18 armored T cell therapies?

  2026cites this paper
• Common gamma chain cytokines-driven optimization of chimeric antigen receptor T cells: Mechanistic insights and future directions

  2026cites this paper
• Obstacles and improvement strategies for CAR-T cell therapy in solid tumors

  2026influential citation
• Current state of CAR-T cell therapies for solid tumors.

  2026cites this paper
• CAR T‐cell therapy in autoimmune skin disease

  2026cites this paper
• Stem-like T cells in cancer immunotherapy: biology, regulation and therapeutic targeting

  2026cites this paper
• Overcoming functional and translational challenges of cellular immunotherapies for solid tumors.

  2026cites this paper
• Advances in IL-2 Family Cytokine-Based Cancer Therapies: Overcoming Challenges Through Molecular Engineering and Delivery Strategies.

  2026cites this paper
• IL-18 revives dysfunctional CAR-T cells.

  2025cites this paper
• CAR T cells in pediatric systemic lupus erythematosus

  2025cites this paper
• From preneoplastic lesion to heterogenous tumor: recent insights into hepatoblastoma biology and therapeutic opportunities

  2025influential citation
• JAK-STAT-activated, fratricide-resistant CAR-T cells targeting membrane-bound TNF effectively treat AML and solid tumors

  2025cites this paper
• Neuroimmunology-driven CAR T-cell therapeutics for gliomas: translational challenges and clinical trial paradigm innovation.

  2025cites this paper
• Mouse B cells engineered to express an anti-HPV antibody elicit anti-tumor T cell responses

  2025cites this paper
• Engineered human B cells targeting tumor-associated antigens exhibit antigen presentation and antibody-mediated functions

  2025cites this paper
• Tracing the development of CAR-T cell design: from concept to next-generation platforms

  2025cites this paper
• Harnessing the immunotherapeutic potentials of gamma delta T cells against hematological malignancies

  2025cites this paper
• NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma

  2025cites this paper
• Harnessing the chimeric antigen receptor engineered cells in gastrointestinal cancer immunotherapy.

  2025cites this paper
• Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells.

  2025cites this paper
• CAR-T for Lung Cancers: Challenges and Innovations.

  2025cites this paper
• IL-7 armed binary CAR T cell strategy to augment potency against solid tumors

  2025cites this paper
• Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer

  2025cites this paper
• GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial

  2025cites this paper
• Challenges in the preclinical design and assessment of CAR-T cells

  2025cites this paper
• New targets and new drugs for hepatobiliary cancers.

  2025cites this paper
• Aptamer-based targeted drug delivery and disease therapy in preclinical and clinical applications.

  2025cites this paper
• Optimization of CAR-T therapy based on metabolic remodeling of the tumor immune microenvironment in diffuse large B-cell lymphoma.

  2025cites this paper
• Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells

  2025cites this paper
• Local radiotherapy polarized tumor-associated macrophages enhance the efficacy of Claudin18.2-targeted CAR-T therapy in pancreatic cancer

  2025cites this paper
• Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma

  2025cites this paper
• Strategic innovations: Tackling challenges of immunotherapy in acute myeloid leukemia.

  2025cites this paper
• The molecular blueprint of targeted radionuclide therapy

  2025cites this paper
• In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy

  2025cites this paper
• Overcoming solid-tumor barriers: armored CAR-T cell therapy.

  2025cites this paper
• Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment

  2025cites this paper
• High-plex imaging of hepatoblastoma and adjacent liver in pediatric patients reveals a predominant myeloid infiltrate expressing immune-checkpoints

  2025cites this paper
• CAR-T cells in solid tumors: Challenges and breakthroughs

  2025cites this paper
• Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety

  2025cites this paper
• CAR T cell persistence in cancer.

  2025cites this paper
• Pulmonary Delivery of TCR Bispecific Proteins via Mesenchymal Stem Cells Facilitates Efficient Clearance of Lung Cancers

  2025cites this paper
• Tissue-resident memory CD8+ T cells: master deciphers of the hepatic environment

  2025influential citation
• Engineered T cell therapy for hepatocellular carcinoma: the dawn of precision immunotherapy?

  2025cites this paper
• Cancer gene therapy: historical perspectives, current applications, and future directions

  2025cites this paper
• D3-GPC2-directed CAR T cells are safe and efficacious in preclinical models of neuroblastoma and small cell lung cancer.

  2025cites this paper
• CAR-DLI for ALL, but not without lymphodepletion.

  2025cites this paper
• Regulators of CD8+ T cell exhaustion

  2025cites this paper
• Optimizing CAR T cell therapy for solid tumours: a clinical perspective

  2025cites this paper
• Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma.

  2025cites this paper
• Advancing CAR-T Therapy for Solid Tumors: From Barriers to Clinical Progress

  2025cites this paper
• Decoding signaling architectures: CAR versus TCR dynamics in solid tumor immunotherapy

  2025cites this paper
• B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors

  2025cites this paper
• Advances in CAR-T cell therapy for refractory diseases: challenges, innovations, clinical breakthroughs, and future prospects

  2025influential citation
• NIR-II fluorescence membrane probes for rapidly labelling hybrid of probiotic outer membrane vesicles and anti-PD-L1 scFv over-expressing cellular vesicles with targeted photothermal-immunotherapy of colon cancer.

  2025cites this paper
• Microenvironmental regulation of solid tumour resistance to CAR T cell therapy

  2025cites this paper
• Facts and Hopes of Chimeric Antigen Receptor-Redirected Natural Killer T cells.

  2025cites this paper
• A Tonic Signaling Code Predicts CAR-T Cell Efficacy in Diffuse Midline Glioma

  2025cites this paper
• Cis-delivering releasable IL-15 superagonist enhances antitumor immunity in cold tumors by invigorating preexisting CD25+CD8+ T cells

  2025cites this paper
• Current Progress of Cell Therapy Clinical Trials in China in 2014–2024

  2025cites this paper
• Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies

  2025cites this paper
• Recent advances in CAR-MSCs: the new engine of cellular immunotherapy evolution

  2025cites this paper
• The landscape of CAR-engineered innate immune cells for cancer immunotherapy

  2025cites this paper
• New advances on the interaction between internal and external factors in the tumor microenvironment of solid tumors

  2025influential citation
• CAR-T cell therapy: A therapeutic strategy for cancer treatment.

  2025cites this paper
• The intersection of CAR-T immunotherapy with emerging technologies.

  2025cites this paper
• Gene Therapy Strategies for Hepatocellular Carcinoma (HCC): Current Landscape and Future Directions

  2025cites this paper
• GD2-CAR–Engineered Microglia Exhibit Antitumor Effects in Organoids and Animal Models of Retinoblastoma

  2025cites this paper
• Improving surgical treatments for hepatocellular carcinoma

  2025cites this paper
• Protein catenation potentiates antitumor activity of malaria VAR2CSA navigation CAR-T cells in a mouse model of hematological malignancies

  2025cites this paper
• IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy.

  2025cites this paper